Hong Kong’s Chapter 18A Biotech Sector: From Financing Access to Global Value Creation

View our Complimentary Blue Book

Since its introduction in 2018, Chapter 18A of the HKEX Listing Rules has reshaped the financing landscape for pre-revenue biotech companies, establishing Hong Kong as a key gateway connecting Chinese innovation with global capital. Following a full cycle of rapid expansion, valuation correction, and structural recovery, the sector is increasingly shifting from pipeline-driven expectations toward commercialization, global business development, and sustainable value creation.

Against the backdrop of accelerating technological innovation and renewed capital-market activity, Chapter 18A companies are advancing across innovative drugs, cell and gene therapies, nucleic acid therapeutics, medical devices, AI-enabled drug discovery, and other frontier fields. To build long-term competitiveness, companies must strengthen clinical execution, accelerate commercialization, expand cross-border licensing and strategic partnerships, improve capital efficiency, and integrate ESG considerations into corporate governance and operational decision-making.

Download this complimentary Blue book to discover:

R

Overall Performance and Evolving Cycles of Global Biotech Capital Markets

R

Key Growth Drivers and Emerging Technology Trends in Hong Kong’s Chapter 18A Biotech Sector

R

Company Profiles and Innovation Pipelines of Chapter 18A-listed Biotech Companies

R

Pre-IPO Financing, Offering Structures, Valuation, Subscription, and Post-listing Performance

R

ESG Policies, Ratings, and Material Sustainability Issues for Chapter 18A Biotech Companies

R

The Competitive Landscape of Sponsors, Industry Consultants, Legal Advisers, Auditors, and Cornerstone Investors in Hong Kong IPOs

View Blue Book Now

Default PDF Reader

Fullscreen Mode

Register to Download the Blue Book To-go

"*" indicates required fields

Comments

This field is for validation purposes and should be left unchanged.

Name*

Job Title*

Company*

Phone*

Business Email*

Country*

Company Size*

CAPTCHA

60 YEARS OF INSIGHTS

Our Global Initiatives



Empower innovation, echoing the voices of emerging technologies and companies, shaping progressive pathways in a dynamic market.



Growth Opportunity content distribution to offer a one-stop platform providing a 360-degree global perspective on the latest industry developments, events, and advancements.



Partner to equip your company with insights and enable capitalization on growth opportunities, ensuring your queries are addressed in a global marketplace.

Download Blue Book Now

ABOUT THE ANALYST

Kim He

Project Manager of Frost & Sullivan Greater China, participated in market research projects, focusing on medicine and medical device industry.

About Our Firm

Frost & Sullivan

Frost & Sullivan has partnered with clients for more than 60 years, developing growth strategies centered on innovation, disruptive technologies, emerging markets, Mega Trends, and new business models.